Last reviewed · How we verify

Aspirin 325mg

University of Utah · FDA-approved active Small molecule Quality 5/100

Aspirin 325mg, developed by the University of Utah, is a marketed drug with a well-established presence in the pharmaceutical market. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity. The primary risk is the potential increase in competition following the patent expiry.

At a glance

Generic nameAspirin 325mg
Also known asASA, Aspirin, Bayer, Salicylic acid, Acetylsalicylic acid
SponsorUniversity of Utah
Drug classNonsteroidal Anti-inflammatory Drug [EPC]
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: